<DOC>
	<DOCNO>NCT01068782</DOCNO>
	<brief_summary>This study multiple regimens single-agent XL184 subject grade IV astrocytic tumor first second relapse . The Randomized Phase study evaluate safety , tolerability , preliminary efficacy four XL184 dose regimen separate study arm . Subjects randomize one study arm , blind . After Randomized Phase , additional subject enrol expand one study arm Expansion Phase .</brief_summary>
	<brief_title>Study Multiple Doses Regimens XL184 ( Cabozantinib ) Subjects With Grade IV Astrocytic Tumors First Second Relapse</brief_title>
	<detailed_description />
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Glioblastoma</mesh_term>
	<criteria>The subject histologically confirm diagnosis time grade IV astrocytic tumor determine investigator . Tumor sample require pathology review . The subject receive prior standard radiation grade astrocytic tumor . The subject receive prior temozolomide ( Temodar ) therapy The subject one two progression grade IV astrocytic tumor grade , determine investigator The subject must qualify brain MRI scan within specific timeframe prior start study treatment For subject recent tumor resection biopsy , start study must occur specified amount time surgery subject must recover effect surgery The subject Karnofsky Performance Status ≥ 70 % ability swallow whole capsule The subject capable understanding inform consent sign informed consent document The subject adequate organ marrow function Sexually active subject ( male female ) must agree use medically accept method contraception course study 6 month follow discontinuation study treatment The subject diagnosis malignancy ( certain exception apply ) Female subject childbearing potential must negative pregnancy test screen The subject receive certain prior anticancer therapy within certain amount time start study treatment The subject receive warfarin ( coumarin derivative ) unable switch low molecular weight heparin The subject evidence acute intracranial intratumoral hemorrhage either MRI CT scan . Subjects resolve hemorrhage change , punctate hemorrhage , hemosiderin eligible The subject unable undergo MRI scan ( eg , pacemaker ) The subject receive enzymeinducing antiepileptic agent within certain time prior start study treatment ( eg , carbamazepine , phenytoin , phenobarbital , primidone ) The subject recover National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) v3.0 Grade ≤ 1 AEs ( except alopecia lymphopenia ) due surgery , medication administer prior study start The subject evidence unhealed wound The subject pregnant breastfeed The subject serious intercurrent illness recent history serious disease The subject inherit bleed diathesis coagulopathy ( disease affect blood clot ) risk bleed The subject history medical surgical condition ( eg , stomach intestinal surgery resection ) would potentially interfere alter gastrointestinal function The subject history idiopathic pulmonary fibrosis interstitial lung disease The subject receive live virus vaccine inactivate vaccine within certain amount time start study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Glioblastoma</keyword>
	<keyword>Glioma</keyword>
	<keyword>Brain Cancer</keyword>
	<keyword>Brain Tumor</keyword>
	<keyword>Astrocytoma</keyword>
</DOC>